China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
47 hedge funds and large institutions have $593M invested in China Biologic Products Holdings, Inc. in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
550% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more funds holding
Funds holding: 25 → 47 (+22)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
46% more capital invested
Capital invested by funds: $407M → $593M (+$186M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.64M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$14M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$9.22M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.34M |
| 4 |
Morgan Stanley
New York
|
+$7.06M |
| 5 |
EMR
Errol M. Rudman
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$2.21M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$768K |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$420K |
| 4 |
NA
Navellier & Associates
Reno,
Nevada
|
-$218K |
| 5 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$154K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$776 | -19 | -76% |
|
CBPO Hedge Fund Activity: Q2 2014 in Review
47 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2014, worth a combined $593M — up 46% from $407M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CBPO positions and 4 closed out — a net gain of 22 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Visium Asset Management, adding an estimated $14M. The largest seller was HSBC Holdings, cutting an estimated $2.21M.
- 47 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2014, up from 25 in Q1 2014.
- Funds reported $593M of China Biologic Products Holdings, Inc. stock for Q2 2014, up 46% quarter-over-quarter.
- 26 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2014 and 4 closed out, a net change of +22 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2014 was Visium Asset Management, an estimated $14M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2014 was HSBC Holdings, an estimated $2.21M sold.
Based on aggregated 13F filings for Q2 2014.